Charles Rhyee

“And maybe just a follow-up then, maybe, Kevin, just from a modeling perspective then, should we think back to maybe two years ago what the backlog conversion rate, and I would assume backlog conversion rate would just fall out naturally because of the mix, because the oncology trials are longer in duration?”

“You know, if we're walking through sort of the guidance here, you know, obviously you're raising organic revenue, you're maintaining adjusted HEPA dot guide. It appears that maybe we saw fast and expect decline implementations, which benefits revenue, but may be true of higher OPEX.”

“And first, let me echo congrats to the both of you going forward here.”

“Maybe just follow up from Whit's question and just at least thinking through for the segments related to the overall EBITDA guidance. Obviously, with the provider segment, we're going to add in sort of the 30 million contribution from the Metasys transaction here.”

“You know, Brett or Brian, I just wanted to ask, you know, obviously strong results here And, you know, you saw accelerating core growth in both North America Pharma and Oncology and multi-specialty by our estimates here.”